Alpha-2 integrin: A protein predictor of tumor spread?
- Date:
- December 6, 2010
- Source:
- Journal of Clinical Investigation
- Summary:
- A new study suggests that decreased expression of the protein alpha-2 integrin is predictive of tumor dissemination to distant sites and decreased survival in individuals with either breast or prostate cancer.
- Share:
Mary Zutter and colleagues, at Vanderbilt University Medical Center, Nashville, have generated data that lead them to suggest that decreased expression of the protein alpha-2 integrin is predictive of tumor dissemination to distant sites and decreased survival in individuals with either breast or prostate cancer.
The researchers first studied the role of the protein alpha-2-beta-1 integrin (which is composed of the alpha-2 integrin protein and the beta-1 integrin protein) in cancer initiation and progression using a clinically relevant, spontaneous mouse model of breast cancer progression and metastasis (spread). Their data indicated that alpha-2-beta-1 integrin suppressed metastasis.
To investigate whether the data had any immediate clinical applicability, a systematic analysis of microarray databases of human breast and prostate cancer was performed. The results of this analysis showed that decreased expression of the gene responsible for generating alpha-2 integrin was predictive of metastasis and decreased survival, leading to the suggestion that alpha-2 integrin expression could be a useful biomarker of metastatic potential and patient survival.
The research is published in the Journal of Clinical Investigation.
Story Source:
Materials provided by Journal of Clinical Investigation. Note: Content may be edited for style and length.
Journal Reference:
- norma E. Ramirez, Zhonghua Zhang, Aasakiran Madamanchi, Kelli L. Boyd, Lynda D. O’Rear, Abudi Nashabi, Zhengzi Li, William D. Dupont, Andries Zijlstra and Mary M. Zutter. The α2β1 integrin is a metastasis suppressor in mouse models and human cancer. Journal of Clinical Investigation, 2010; DOI: 10.1172/JCI42328
Cite This Page: